middle.news
Syntara’s Amsulostat Shows Strong Phase 2a Results in Myelofibrosis Trial
9:12am on Tuesday 30th of September, 2025 AEST
•
Healthcare
Read Story
Syntara’s Amsulostat Shows Strong Phase 2a Results in Myelofibrosis Trial
9:12am on Tuesday 30th of September, 2025 AEST
Key Points
73% of patients achieved 50% symptom improvement at 24 weeks or beyond
44% of evaluable patients showed meaningful spleen volume reduction
Amsulostat demonstrated a distinct mode of action targeting bone marrow fibrosis
Well-funded with A$20.7 million cash runway into 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE